The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
Chronic myeloid leukaemia (CML) is driven by the activity of the BCR-ABL1 fusion oncoprotein. ABL1 kinase inhibitors have improved the clinical outcomes for patients with CML, with over 80% of patients treated with imatinib surviving for more than 10 years. Second-generation ABL1 kinase inhibitors induce more potent molecular responses in both previously untreated and imatinib-resistant patients with CML. Studies in patients with chronic-phase CML have shown that around 50% of patients who achieve and maintain undetectable BCR-ABL1 transcript levels for at least 2 years remain disease-free after the withdrawal of treatment. Here we characterize ABL001 (asciminib), a potent and selective allosteric ABL1 inhibitor that is undergoing clinical development testing in patients with CML and Philadelphia chromosome-positive (Ph^sup +^) acute lymphoblastic leukaemia. In contrast to catalytic-site ABL1 kinase inhibitors, ABL001 binds to the myristoyl pocket of ABL1 and induces the formation of an inactive kinase conformation. ABL001 and second-generation catalytic inhibitors have similar cellular potencies but distinct patterns of resistance mutations, with genetic barcoding studies revealing pre-existing clonal populations with no shared resistance between ABL001 and the catalytic inhibitor nilotinib. Consistent with this profile, acquired resistance was observed with single-agent therapy in mice; however, the combination of ABL001 and nilotinib led to complete disease control and eradicated CML xenograft tumours without recurrence after the cessation of treatment..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:543 |
|---|---|
| Enthalten in: |
Nature |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andrew A Wylie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Crystallography |
|---|
| doi: |
10.1038/nature21702 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1992548374 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1992548374 | ||
| 003 | DE-627 | ||
| 005 | 20230715042234.0 | ||
| 007 | tu | ||
| 008 | 170512s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1038/nature21702 |2 doi | |
| 028 | 5 | 2 | |a PQ20170721 |
| 035 | |a (DE-627)OLC1992548374 | ||
| 035 | |a (DE-599)GBVOLC1992548374 | ||
| 035 | |a (PRQ)p939-2b0d6722e0c3e51644e59ca054dfd5d8dbd9782483fc43ae9de8930d90b96fea0 | ||
| 035 | |a (KEY)0072945020170000543764700733allostericinhibitorabl001enablesdualtargetingofbcr | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 070 |a 500 |q DE-101 |
| 082 | 0 | 4 | |a 500 |q AVZ |
| 084 | |a BIODIV |2 fid | ||
| 100 | 0 | |a Andrew A Wylie |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1 |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Chronic myeloid leukaemia (CML) is driven by the activity of the BCR-ABL1 fusion oncoprotein. ABL1 kinase inhibitors have improved the clinical outcomes for patients with CML, with over 80% of patients treated with imatinib surviving for more than 10 years. Second-generation ABL1 kinase inhibitors induce more potent molecular responses in both previously untreated and imatinib-resistant patients with CML. Studies in patients with chronic-phase CML have shown that around 50% of patients who achieve and maintain undetectable BCR-ABL1 transcript levels for at least 2 years remain disease-free after the withdrawal of treatment. Here we characterize ABL001 (asciminib), a potent and selective allosteric ABL1 inhibitor that is undergoing clinical development testing in patients with CML and Philadelphia chromosome-positive (Ph^sup +^) acute lymphoblastic leukaemia. In contrast to catalytic-site ABL1 kinase inhibitors, ABL001 binds to the myristoyl pocket of ABL1 and induces the formation of an inactive kinase conformation. ABL001 and second-generation catalytic inhibitors have similar cellular potencies but distinct patterns of resistance mutations, with genetic barcoding studies revealing pre-existing clonal populations with no shared resistance between ABL001 and the catalytic inhibitor nilotinib. Consistent with this profile, acquired resistance was observed with single-agent therapy in mice; however, the combination of ABL001 and nilotinib led to complete disease control and eradicated CML xenograft tumours without recurrence after the cessation of treatment. | ||
| 650 | 4 | |a Kinases | |
| 650 | 4 | |a Nuclear magnetic resonance--NMR | |
| 650 | 4 | |a Phosphorylation | |
| 650 | 4 | |a Crystallography | |
| 650 | 4 | |a Patients | |
| 650 | 4 | |a Studies | |
| 650 | 4 | |a Mutation | |
| 650 | 4 | |a Hypotheses | |
| 700 | 0 | |a Joseph Schoepfer |4 oth | |
| 700 | 0 | |a Wolfgang Jahnke |4 oth | |
| 700 | 0 | |a Sandra W Cowan-Jacob |4 oth | |
| 700 | 0 | |a Alice Loo |4 oth | |
| 700 | 0 | |a Pascal Furet |4 oth | |
| 700 | 0 | |a Andreas L Marzinzik |4 oth | |
| 700 | 0 | |a Xavier Pelle |4 oth | |
| 700 | 0 | |a Jerry Donovan |4 oth | |
| 700 | 0 | |a Wenjing Zhu |4 oth | |
| 700 | 0 | |a Silvia Buonamici |4 oth | |
| 700 | 0 | |a A Quamrul Hassan |4 oth | |
| 700 | 0 | |a Franco Lombardo |4 oth | |
| 700 | 0 | |a Varsha Iyer |4 oth | |
| 700 | 0 | |a Michael Palmer |4 oth | |
| 700 | 0 | |a Giuliano Berellini |4 oth | |
| 700 | 0 | |a Stephanie Dodd |4 oth | |
| 700 | 0 | |a Sanjeev Thohan |4 oth | |
| 700 | 0 | |a Hans Bitter |4 oth | |
| 700 | 0 | |a Susan Branford |4 oth | |
| 700 | 0 | |a David M Ross |4 oth | |
| 700 | 0 | |a Timothy P Hughes |4 oth | |
| 700 | 0 | |a Lilli Petruzzelli |4 oth | |
| 700 | 0 | |a K Gary Vanasse |4 oth | |
| 700 | 0 | |a Markus Warmuth |4 oth | |
| 700 | 0 | |a Francesco Hofmann |4 oth | |
| 700 | 0 | |a Nicholas J Keen |4 oth | |
| 700 | 0 | |a William R Sellers |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nature <London> |d London : Macmillan, 1869 |g 543(2017), 7647, Seite 733 |w (DE-627)129292834 |w (DE-600)120714-3 |w (DE-576)014473941 |x 0028-0836 |7 nnns |
| 773 | 1 | 8 | |g volume:543 |g year:2017 |g number:7647 |g pages:733 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1038/nature21702 |3 Volltext |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1884793170 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHY | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-MAT | ||
| 912 | |a SSG-OLC-FOR | ||
| 912 | |a SSG-OLC-SPO | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-FOR | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_14 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_47 | ||
| 912 | |a GBV_ILN_48 | ||
| 912 | |a GBV_ILN_59 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_135 | ||
| 912 | |a GBV_ILN_154 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_211 | ||
| 912 | |a GBV_ILN_252 | ||
| 912 | |a GBV_ILN_290 | ||
| 912 | |a GBV_ILN_294 | ||
| 912 | |a GBV_ILN_601 | ||
| 912 | |a GBV_ILN_647 | ||
| 912 | |a GBV_ILN_754 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2002 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2016 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2095 | ||
| 912 | |a GBV_ILN_2116 | ||
| 912 | |a GBV_ILN_2120 | ||
| 912 | |a GBV_ILN_2121 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_2221 | ||
| 912 | |a GBV_ILN_2279 | ||
| 912 | |a GBV_ILN_2286 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4277 | ||
| 912 | |a GBV_ILN_4302 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4314 | ||
| 912 | |a GBV_ILN_4317 | ||
| 912 | |a GBV_ILN_4320 | ||
| 912 | |a GBV_ILN_4324 | ||
| 951 | |a AR | ||
| 952 | |d 543 |j 2017 |e 7647 |h 733 | ||